

# Christian Ellermann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6784661/publications.pdf>

Version: 2024-02-01

54  
papers

439  
citations

840776

11  
h-index

888059

17  
g-index

56  
all docs

56  
docs citations

56  
times ranked

508  
citing authors

#	ARTICLE	IF	CITATIONS
1	Electrophysiologic effects of sacubitril in different arrhythmia models. <i>European Journal of Pharmacology</i> , 2022, 917, 174747.	3.5	0
2	The Incidence, Electrophysiological Characteristics and Ablation Outcome of Left Atrial Tachycardias after Pulmonary Vein Isolation Using Three Different Ablation Technologies. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 50.	1.6	2
3	Incidence and Predictors of Left Atrial Appendage Thrombus before Catheter Ablation of Thrombogenic Arrhythmias. <i>Journal of Personalized Medicine</i> , 2022, 12, 460.	2.5	0
4	Cardiovascular risk of energy drinks: Caffeine and taurine facilitate ventricular arrhythmias in a sensitive whole-heart model. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 1290-1297.	1.7	5
5	Divergent Electrophysiological Effects of Loperamide and Naloxone in a Sensitive Whole-Heart Model. <i>Cardiovascular Toxicology</i> , 2021, 21, 248-254.	2.7	3
6	Pitfalls of the S-ICD therapy: experiences from a large tertiary centre. <i>Clinical Research in Cardiology</i> , 2021, 110, 861-867.	3.3	6
7	Role of the rabbit whole-heart model for electrophysiologic safety pharmacology of non-cardiovascular drugs. <i>Europace</i> , 2021, 23, 828-836.	1.7	8
8	Predictors of AVNRT Recurrence After Slow Pathway Modification. <i>International Heart Journal</i> , 2021, 62, 72-77.	1.0	3
9	Proarrhythmic potential of metoclopramide in a sensitive whole-heart model. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 741-746.	2.5	2
10	Pre-procedural proton pump inhibition is associated with fewer peri-oesophageal lesions after cryoballoon pulmonary vein isolation. <i>Scientific Reports</i> , 2021, 11, 4728.	3.3	7
11	High-Density Mapping Revealing Figure-of-Eight Re-Entrant Atrial Tachycardia in Uhl's Anomaly. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 1074-1075.	3.2	0
12	Quantifying Left Atrial Size in the Context of Atrial Fibrillation Ablation: Which Echocardiographic Method Correlates to Outcome of Pulmonary Venous Isolation?. <i>Journal of Personalized Medicine</i> , 2021, 11, 913.	2.5	1
13	Predictors of response to cardiac resynchronization therapy in patients with chronic right ventricular pacing. <i>Clinical Research in Cardiology</i> , 2021, 110, 877-883.	3.3	3
14	Very Long-Term Follow-Up in Cardiac Resynchronization Therapy: Wider Paced QRS Equals Worse Prognosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1176.	2.5	1
15	Safe electrophysiologic profile of dexmedetomidine in different experimental arrhythmia models. <i>Scientific Reports</i> , 2021, 11, 23940.	3.3	6
16	Action Potential Triangulation Explains Acute Proarrhythmic Effect of Aliskiren in a Whole-Heart Model of Atrial Fibrillation. <i>Cardiovascular Toxicology</i> , 2020, 20, 49-57.	2.7	3
17	Proarrhythmic Effect of Acetylcholine-Esterase Inhibitors Used in the Treatment of Alzheimer's Disease: Benefit of Rivastigmine in an Experimental Whole-Heart Model. <i>Cardiovascular Toxicology</i> , 2020, 20, 168-175.	2.7	14
18	Long-term experience of atrioventricular node ablation in patients with refractory atrial arrhythmias. <i>Heart and Vessels</i> , 2020, 35, 699-704.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Outcome differences and device performance of the subcutaneous ICD in patients with and without structural heart disease. <i>Clinical Research in Cardiology</i> , 2020, 109, 755-760.	3.3	6
20	The role of entirely subcutaneous ICD systems in patients with dilated cardiomyopathy. <i>Journal of Cardiology</i> , 2020, 75, 567-570.	1.9	6
21	Prospective blinded Evaluation of the smartphone-based AliveCor Kardia ECG monitor for Atrial Fibrillation detection: The PEAK-AF study. <i>European Journal of Internal Medicine</i> , 2020, 73, 72-75.	2.2	52
22	Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real-world data on safety and efficacy. <i>Clinical Cardiology</i> , 2020, 43, 1579-1584.	1.8	3
23	Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation. <i>Pharmaceuticals</i> , 2020, 13, 321.	3.8	3
24	Outcome of catheter ablation in the very elderly—insights from a large matched analysis. <i>Clinical Cardiology</i> , 2020, 43, 1423-1427.	1.8	2
25	Propofol abolishes torsade de pointes in different models of acquired long QT syndrome. <i>Scientific Reports</i> , 2020, 10, 12133.	3.3	6
26	Concomitant Treatment with Proton Pump Inhibitors and Cephalosporins Does Not Enhance QT-Associated Proarrhythmia in Isolated Rabbit Hearts. <i>Cardiovascular Toxicology</i> , 2020, 20, 531-538.	2.7	2
27	Die Refluxösophagitis ist ein Risikofaktor für das Auftreten von perösophagealen Läsionen nach Vorhofflimmerablation. , 2020, 58, .		0
28	Follow-up of the first patients with a totally subcutaneous ICD in Germany from implantation till battery depletion. <i>Clinical Research in Cardiology</i> , 2019, 108, 16-21.	3.3	14
29	Acute electrophysiologic effects of the polyphenols resveratrol and piceatannol in rabbit atria. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 94-98.	1.9	9
30	Outcome of catheter ablation of supraventricular tachyarrhythmias in cardiac sarcoidosis. <i>Clinical Cardiology</i> , 2019, 42, 1121-1125.	1.8	4
31	Time-to-isolation-guided cryoballoon ablation reduces oesophageal and mediastinal alterations detected by endoscopic ultrasound: results of the MADE-PVI trial. <i>Europace</i> , 2019, 21, 1325-1333.	1.7	21
32	Feasibility of entirely subcutaneous ICD systems in patients with coronary artery disease. <i>Clinical Research in Cardiology</i> , 2019, 108, 1234-1239.	3.3	9
33	Diagnosis and management of cold urticaria in cryoablation of atrial fibrillation: a case report. <i>European Heart Journal - Case Reports</i> , 2019, 3, 1-5.	0.6	4
34	Remaining challenges in catheter ablation of accessory pathways: rare entity of coronary sinus diverticulum-associated pathways. <i>Clinical Research in Cardiology</i> , 2019, 108, 388-394.	3.3	6
35	Digitalis Promotes Ventricular Arrhythmias in Flecainide- and Ranolazine-Pretreated Hearts. <i>Cardiovascular Toxicology</i> , 2019, 19, 237-243.	2.7	4
36	Ivabradine Aggravates the Proarrhythmic Risk in Experimental Models of Long QT Syndrome. <i>Cardiovascular Toxicology</i> , 2019, 19, 129-135.	2.7	8

#	ARTICLE	IF	CITATIONS
37	Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes. <i>Europace</i> , 2018, 20, 1699-1706.	1.7	12
38	Ryanodineâ€receptor inhibition by dantrolene effectively suppresses ventricular arrhythmias in an <i>ex vivo</i> model of longâ€QT syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 471-476.	1.7	5
39	Broad antiarrhythmic effect of mexiletine in different arrhythmia models. <i>Europace</i> , 2018, 20, 1375-1381.	1.7	22
40	Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents. <i>Cardiovascular Toxicology</i> , 2018, 18, 84-90.	2.7	17
41	Ranolazine Prevents Levosimendan-Induced Atrial Fibrillation. <i>Pharmacology</i> , 2018, 102, 138-141.	2.2	7
42	Change of sensing vector in the subcutaneous ICD during followâ€up and after device replacement. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1241-1247.	1.7	8
43	Acute infusion of levosimendan enhances atrial fibrillation in an experimental whole-heart model. <i>International Journal of Cardiology</i> , 2017, 236, 423-426.	1.7	8
44	Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug?. <i>International Journal of Cardiology</i> , 2017, 236, 237-243.	1.7	14
45	Severe Proarrhythmic Potential of the Antiemetic Agents Ondansetron and Domperidone. <i>Cardiovascular Toxicology</i> , 2017, 17, 451-457.	2.7	14
46	Divergent antiarrhythmic effects of resveratrol and piceatannol in a whole-heart model of long QT syndrome. <i>International Journal of Cardiology</i> , 2017, 243, 233-238.	1.7	8
47	Ivabradine Reduces Digitalisâ€induced Ventricular Arrhythmias. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 526-530.	2.5	11
48	Antiarrhythmic properties of ivabradine in an experimental model of Shortâ€QTâ€Syndrome. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 941-945.	1.9	14
49	Interactions of digitalis and class-III antiarrhythmic drugs: Amiodarone versus dronedarone. <i>International Journal of Cardiology</i> , 2017, 228, 74-79.	1.7	11
50	The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 1155-1161.	3.0	9
51	Antiarrhythmic effect of vernakalant in an experimental model of Long-QT-syndrome. <i>Europace</i> , 2017, 19, 866-873.	1.7	7
52	Experimental evidence for a severe proarrhythmic potential of levosimendan. <i>International Journal of Cardiology</i> , 2017, 228, 583-587.	1.7	8
53	Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Wholeâ€Heart Model of Short QT Syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 1214-1219.	1.7	33
54	Considering Ranolazine as a Potential Treatment for K <sup>+</sup> Channel Linked Short QT Syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, E6.	1.7	0